NeuroInDx, Inc. is a development stage biotechnological company focused on discovering, developing and commercializing novel technologies and platforms for the studies of Central Nervous System (CNS) and diagnostics of CNS disorders and metabolic diseases using innovative high-tech approaches in functional genomics.
The goal of NeuroInDx, Inc. is to develop novel technologies and instruments for the analysis and acquisition of CNS and other tissues, to discover novel disease markers and to develop novel genomic techniques. To expand its pipeline and generate revenue, NeuroInDx, Inc. is applying its proprietary technologies and genomic platforms through strategic collaborations with governmental agencies, pharmaceutical companies and academic institutions.
NeuroInDx, Inc. whole technology and target discovery collaborations and internal research programs are expected to yield considerable efficiency gains compared to traditional animal-based techniques, resulting in faster, less-expensive, and more clinically relevant target identification and development programs.
Primarily NeuroInDx’s goal is to become a leading technological company focused on developing and commercializing a novel cell and tissue acquisition technology. We are developing an internal pipeline of products to provide late-stage product opportunities for large biotechnological companies. Our technologies at various phases of commercialization are available for testing, evaluation and licensing.